Clinical effect of mifepristone on patients with ovarian cancer in pregnancy.
At present, the main methods of clinical treatment of ovarian cancer are cytoreductive surgery and multidrug combination chemotherapy, in which multidrug combination chemotherapy is based on platinum drugs. Mifepristone can be used as an adjuvant drug for the treatment of drug-resistant and refractory ovarian cancer because of its convenient oral administration, long half-life, low cytotoxicity to normal cells, anti-tumor activity and chemosensitizing effect. This article analyzed the clinical effect of mifepristone combined with bevacizumab in the treatment of patients with ovarian cancer. Sixty patients were randomly divided into experimental group and control group. Mifepristone combined with bevacizumab was used in experimental group and conventional anticancer drugs were used in control group. The results showed that the amount of bleeding during labor (6.38±1.85 mL), the rate of birth injury (0%) and the amount of bleeding 2 hours after delivery (63.12±19.86 mL) in the experimental group were significantly better than those in the control group (P<0.05), and the incidence of side effects and complications were significantly lower than those in the control group (P<0.05). In conclusion, mifepristone combined with bevacizumab in the treatment of high-risk pregnancy complicated with ovarian cancer can significantly reduce the patient's labor process and the amount of bleeding at different stages after surgery, the incidence of side effects and complications after surgery is significantly reduced, which is conducive to the recovery of the patient's body. .